Current Health Expands Advanced Therapy Support with Integrated Virtual ICANS Assessments

Boston, MA — Current Health today announced the launch of virtual ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) assessments, delivering the most complete, scalable solution for standardized remote neurotoxicity evaluations. This advancement complements Current Health’s industry-leading capabilities in early detection of Cytokine Release Syndrome (CRS), enabling comprehensive support for both major toxicities associated with CAR-T and bispecific T-cell engager therapies.

ICANS assessments—typically conducted in the hospital or clinic—are a critical component of advanced therapy care, but often create care delays, strain provider resources, and disrupt the patient and caregiver experience. Current Health’s new functionality allows these evaluations to be conducted remotely via video visit, including the full ICE (Immune Effector Cell-Associated Encephalopathy) score with handwriting assessment, all integrated into the clinical dashboard for easy trend comparison.

In addition to expanding capabilities for provider teams, Current Health’s Clinical Command Center—staffed 24/7 with specialized nurses trained in managing advanced therapies—will now conduct ICANS assessments for advanced therapy programs. This service gives care teams greater flexibility while ensuring consistent, expert evaluations aligned with protocols.

This launch directly supports the industry-wide shift toward outpatient administration of CAR-T and bispecific therapies, enabling both provider organizations and pharma companies to expand access, improve efficiency, and deliver a more patient-centric experience. Neurotoxicity and cytokine release syndrome (CRS) are the most common and potentially life-threatening toxicities associated with these treatments. By supporting detection and escalation for both, Current Health uniquely positions itself as the clinical support layer for advanced therapy programs, enabling broader access to approved products and clinical trials.

“As advanced therapies become more widely adopted, providers and pharma sponsors need reliable ways to scale access without sacrificing safety. By enabling remote detection and escalation for both CRS and ICANS, we’re helping our partners move these high-acuity treatments closer to patients—safely, efficiently, and with confidence,” said Chris McGhee, CEO and Co-Founder of Current Health.

Key benefits of the new ICANS assessment feature include:

• Seamless integration with early CRS detection, creating complete early detection protocols that allow patients to remain home longer without compromising safety.
• Operational efficiency, reducing provider burden and supporting easier and more consistent adherence to protocols.
• Improved patient and caregiver experience, reducing unnecessary travel during recovery while improving real-time clinical oversight.
• Longitudinal documentation, enabling comparison of prior assessments to detect subtle neurological changes.
• Clinical flexibility, with assessments performed by either institutional teams or Current Health’s Clinical Command Center using the new tool.

With this launch, Current Health continues to set the standard for scalable outpatient advanced therapy support that protects safety and reduces complexity for clinical teams.